Navigation Links
Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
Date:5/31/2008

t. After median follow up of 13.6 months, median progression-free survival and overall survival have not been reached. Side effects were manageable and included hematologic toxicity and peripheral neuropathy.

Safety and Efficacy of Lenalidomide, VELCADE and dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: A Phase I/II Study (Abstract #8520)

This Phase I/II study of VcRD combination therapy was designed to determine the maximum tolerated dose (MTD) and efficacy in previously untreated MM patients. The preliminary analysis included 66 evaluable patients, who received VELCADE at 1.0 mg/m2 or 1.3 mg/m2 on days 1, 4, 8 and 11 of a 21-day schedule. Patients also received lenalidomide at 15, 20 or 25 mg on days 1 through 14 and dexamethasone at 40 or 20 mg on the day of and day after each VELCADE dose. Patients were treated for up to eight cycles at four planned dose levels. Maximum planned dose was VELCADE 1.3 mg/m2, lenalidomide 25 mg and dexamethasone 20 mg. Response was assessed by modified EBMT criteria and International Myeloma Working Group criteria. Results were presented by Paul Richardson, M.D., Associate Professor of Medicine, Harvard Medical School; Clinical Director, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston and showed a CR rate of 35 percent at maximum planned dose and a 100 percent overall response rate (CR + partial response). Side effects were manageable and included lymphopenia, thrombocytopenia, hypophosphatemia and neutropenia. No grade 4 peripheral neuropathy was observed.

About Multiple Myeloma

Multiple myeloma is the second most common hematologic malignancy and although the disease is predominantly a cancer of the elderly (the median age of onset is 70 years), recent statistics indicate both increasing incidence and younger age of onset. In the U.S., more than 50,000 individuals have MM and 20,000 new cases are diagnosed each year. Worldwide there are approximately 74,000
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... SM , the nation,s leader in medication monitoring solutions, ... M.D., as Chief Medical Officer. In this role, Smith ... healthcare providers, patients and managed care plans.   ... of healthcare companies that have provided him with experiences ... sides of Ameritox,s business. He most recently served as ...
(Date:10/17/2014)... 17, 2014   ndd Medical Technologies , a ... precise ultrasound technology, announced that its EasyOne Pro® is ... Center , a 140,000 square foot, 44-bed hospital with ... hospital serves a large number of Native Americans ... and beyond. A portion of its funding ...
(Date:10/17/2014)... Calif. , Oct. 17, 2014  STAAR Surgical Company ... of implantable lenses and delivery systems for the eye, today ... Investor Breakfast Meeting on Saturday, October 18, 7:00 a.m. CT ... Chicago, IL. Dr. ... Eye Centre in Antwerp, Belgium , will ...
Breaking Medicine Technology:Ameritox Appoints New Chief Medical Officer 2EasyOne Pro Mobile Respiratory Testing from ndd Medical Technologies Chosen by Choctaw Nation 2STAAR Surgical to Webcast Investor Presentations at American Academy of Ophthalmology's Annual Meeting 2STAAR Surgical to Webcast Investor Presentations at American Academy of Ophthalmology's Annual Meeting 3
... VIEW, Calif., May 1, 2012 MAP Pharmaceuticals, Inc. (Nasdaq: ... the following investor conferences in May 2012: Deutsche Bank ... in Boston Bank of America Merrill Lynch 2012 Healthcare ... A live webcast of each event will be available ...
... May 1, 2012 /PRNewswire-iReach/ -- GenWay Biotech ... company,s new Vice President of GenWay Custom/OEM. This position ... focus on growth of the individual divisions including GenWay ... Biotech has provided the diagnostic and research communities with ...
Cached Medicine Technology:GenWay Biotech Appoints New Vice President of Custom/OEM 2GenWay Biotech Appoints New Vice President of Custom/OEM 3
(Date:10/19/2014)... The leading review website, Top10BestSEOHosting.com, has ... GreenGeeks are the best Dedicated Server Hosting suppliers. ... want to buy high quality hosting and save ... manager of Top10BestSEOHosting.com says, “We believe that iPage ... everyone. A lot of the global clients enjoy ...
(Date:10/19/2014)... This report provides comprehensive information on ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ... late-stage and discontinued projects. , Partial Seizures are ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that provides many ... latest designs of 2014 mother of the bride ... are offered with big discounts, up to 70% off. ... can enjoy this special offer. , Owing to ... become one of the leading brands in the global ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Stephen T. Greenberg, ... been nominated for the 10th consecutive year as one of ... Dr. Greenberg was also been nominated as the best provider ... also nominated as best Day Spa and best Laser Treatment ... December 14th and readers can vote for the contest once ...
(Date:10/19/2014)... 20, 2014 – The U.S. Government has initiated ... Alzheimer,s disease by 2025. However, a workgroup of ... research milestones in the U.S. Government,s National Plan ... scope, increased in scale, and adequately funded in ... of proposals by the workgroup to enlarge and ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Dr. Stephen T. Greenberg – Nominated for the 10th Consecutive Year for One of Long Island’s Best Cosmetic Surgeons for 2015 by the Long Island Press 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 3Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 4Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 5Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 6
... Thermage, Inc.,(Nasdaq: THRM ), today announced ... Medical, Ltd., a leading distributor of advanced aesthetic,technology ... sales professionals will market the Company,s ThermaCool(R) systems,and ... United States. "We are very pleased to ...
... ... Brussels, HUNTERSVILLE, N.C., Oct. ... it has,acquired the rights to all of the intellectual property related to ... and back pain suffered by,individuals with lumbar spinal stenosis (LSS). The innovative ...
... In people with chronic myeloid leukemia (CML), the drug ... but the disease often returns when treatment is stopped. ... could cure CML under certain circumstances if it is ... Mathematician Natalia Komarova and biologist Dominik Wodarz also developed ...
... Majority Leader Harry Reid issued the following statement this,afternoon ... legislation:, "This afternoon, the Congress sent to President ... nation,s children. It is our hope and the will,of ... bill into law on,behalf of the future. It is ...
... Oct. 2 CYNACON/OCuSOFT (OCuSOFT,Inc.), a company ... ophthalmologists and optometrists, is pleased to announce ... its Optometric Scientific,Advisory Board. *(LOGO: Send2Press.com/mediaboom/07-0803-Occusoft_72dpi.jpg) ... of Omni Eye Surgery in New York,City. ...
... 3 With declining revenues and,shrinking sales forces, ... Affairs, to maximize their sales support role, yet ... goal, leading pharmaceutical,companies run sleek and efficient Medical ... function, thereby ensuring the creation of,winning products. ...
Cached Medicine News:Health News:Thermage, Inc. Announces Distribution Agreement With Eclipse Medical, Ltd. 2Health News:Orthofix International Acquires InSWing(TM) Interspinous Process Spacer 2Health News:Orthofix International Acquires InSWing(TM) Interspinous Process Spacer 3Health News:Drug has ability to cure type of leukemia 2Health News:Medical Affairs: Building Efficient Medical Affairs Functions That Drive Product Marketing Success 2
Bravo Datalink. For upload of Bravo pH data to a PC. Connects to the pcs serial port....
Bravo Calibration Tubes...
pH Calibration Stand with two Sealable Buffer Tubes 1 set....
... catheters are efficient, economical, eliminate the ... patient comfort during the test period., ... have been designed to use temperature ... room-temperature calibration. The temperature correction factors ...
Medicine Products: